All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BEIJING – While acknowledging that China still needs to play catch up in med-tech innovation, Chinese cardiovascular experts are striving to make breakthroughs in bioabsorable stents and transcatheter heart valves with government-backed research projects underway.
BEIJING – Chengdu-based Sichuan Clover Biopharmaceuticals Inc. closed a series B financing round to inject another $43 million into its drug development and manufacturing operations, with a focus on biologic candidate SCB-313, developed with its Trimer-Tag technology platform.
BEIJING – Chinese transcatheter heart valve developer Venus Medtech (Hangzhou) Inc. on Tuesday saw its share prices jump around 20% on its debut on the Hong Kong Stock Exchange (HKEX), an excellent start for a prerevenue med-tech IPO.
